# OnCo record imbassador250 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/imbassador250/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "imbassador250", "NCT03016312" ;
  schema:name "IMbassador250"@en ;
  schema:alternateName "IMbassador250"@en, "IMbassador 250"@en ;
  schema:description "Adding a checkpoint inhibitor to enzalutamide did not help men with advanced prostate cancer live longer, and the trial explained why: prostate tumours carry very little of what these drugs need."@en ;
  schema:url <https://onco.cc/trials/imbassador250/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03016312>, <https://doi.org/10.1038/s41591-021-01600-6> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pten/>, <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/enzalutamide/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/arpi/> ;
  onco:trials <https://onco.cc/trials/keynote-641/>, <https://onco.cc/trials/keynote-921/>, <https://onco.cc/trials/keynote-991/>, <https://onco.cc/trials/ca184-043-ipilimumab/> .